Related Experiment Video
Updated: Mar 29, 2026
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
Heterogeneity in Melanoma
Batool Shannan1, Michela Perego1, Rajasekharan Somasundaram1
1Molecular and Cellular Oncogenesis Program, Melanoma Research Center, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA, 19104, USA.
Abstract:
Melanoma is among the most aggressive and therapy-resistant human cancers. While great strides in therapy have generated enthusiasm, many challenges remain. Heterogeneity is the most pressing issue for all types of therapy. This chapter summarizes the clinical classification of melanoma, of which the research community now adds additional layers of classifications for better diagnosis and prediction of therapy response. As the search for new biomarkers increases, we expect that biomarker analyses will be essential for all clinical trials to better select patient populations for optimal therapy. While individualized therapy that is based on extensive biomarker analyses is an option, we expect in the future genetic and biologic biomarkers will allow grouping of melanomas in such a way that we can predict therapy outcome. At this time, tumor heterogeneity continues to be the major challenge leading inevitably to relapse. To address heterogeneity therapeutically, we need to develop complex therapies that eliminate the bulk of the tumor and, at the same time, the critical subpopulations.
Insights
Melanoma, a challenging cancer, faces therapy resistance due to tumor heterogeneity. Future treatments require complex strategies targeting diverse cancer cell populations for improved outcomes.
Area of Science:
- Oncology
- Cancer Biology
Background:
- Melanoma is a highly aggressive and therapy-resistant human cancer.
- Tumor heterogeneity presents a significant challenge in melanoma treatment.
- Despite therapeutic advancements, patient relapse remains a critical issue.
Purpose of the Study:
- To summarize current clinical melanoma classification and emerging layers of classification.
- To highlight the increasing importance of biomarkers for diagnosis and predicting therapy response.
- To discuss strategies for addressing tumor heterogeneity in melanoma treatment.
Main Methods:
- Review of clinical melanoma classifications.
- Analysis of emerging diagnostic and predictive biomarkers.
- Discussion of therapeutic strategies to overcome tumor heterogeneity.
Main Results:
- Current melanoma classification is evolving with new diagnostic layers.
- Biomarker analysis is becoming essential for patient selection in clinical trials.
- Tumor heterogeneity is identified as the primary driver of therapeutic failure and relapse.
Conclusions:
- Individualized therapy based on biomarkers is a promising approach.
- Future research aims to group melanomas using genetic and biologic biomarkers for outcome prediction.
- Developing complex therapies to target both bulk tumor and critical subpopulations is crucial for overcoming melanoma heterogeneity and preventing relapse.
Related Concept Videos
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:21Cancers Originate from Somatic Mutations in a Single Cell
02:21Cancers Originate from Somatic Mutations in a Single Cell